Ir al menú de navegación principal Ir al contenido principal Ir al pie de página del sitio

Caracterización de variantes en el exón 28 del gen VWF y su correlación genotipo-fenotipo en una muestra de pacientes con enfermedad de Von Willebrand tipo 2

Characterization of variants in exon 28 of the VWF gene and their genotype-phenotype correlation in a sample of patients with von Willebrand disease type 2.



Abrir | Descargar

Cómo citar

1.
Parada Ferro LK, Linares Ballesteros A, Casas Patarroyo CP, Rodríguez Fiquitiva AD, Suárez Molano C, Yunis Hazbun LK, et al. Caracterización de variantes en el exón 28 del gen VWF y su correlación genotipo-fenotipo en una muestra de pacientes con enfermedad de Von Willebrand tipo 2. Rev. colomb. hematol. oncol. [Internet]. 2025 Jun. 27 [cited 2025 Dec. 5];12(1):56-90. https://doi.org/10.51643/22562915.729

Descargar cita

Citaciones


Sección
Artículos originales

Cómo citar
1.
Parada Ferro LK, Linares Ballesteros A, Casas Patarroyo CP, Rodríguez Fiquitiva AD, Suárez Molano C, Yunis Hazbun LK, et al. Caracterización de variantes en el exón 28 del gen VWF y su correlación genotipo-fenotipo en una muestra de pacientes con enfermedad de Von Willebrand tipo 2. Rev. colomb. hematol. oncol. [Internet]. 2025 Jun. 27 [cited 2025 Dec. 5];12(1):56-90. https://doi.org/10.51643/22562915.729

Dimensions
PlumX
Licencia
Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.


Laura Katherine Parada Ferro ,

Bacterióloga y Laboratorista Clínica, Magister en Genética Humana. 


Adriana Linares Ballesteros,

Especialista en Pediatría, Oncohematología pediátrica y Bioética.


Claudia Patricia Casas Patarroyo ,

Médica Hematóloga.


Andrea Dadeiba Rodríguez Fiquitiva,

Profesional en Enfermería.


Claudia Suárez Molano ,

Profesional en Enfermería.


Luz Karime Yunis Hazbun ,

Médica, MSc. en Genética.


Juan José Yunis Londoño,

Médico, MSc. en Genética. 


Introducción: la enfermedad de Von Willebrand es la coagulopatía hereditaria más común en la población, el abordaje del análisis molecular como apoyo diagnóstico ha sido limitado en la enfermedad de Von Willebrand (EvW) de tipo 2. El objetivo de este estudio es caracterizar las variantes en el exón 28 del gen VWF y realizar la correlación genotipo-fenotipo en una muestra de pacientes con EvW tipo 2. Métodos: se analizaron 20 muestras de pacientes previamente diagnosticados con EvW tipo 2 con edades entre 8 y 56 años. Se realizó análisis del Exón 28 del gen VWF, por amplificación, verificación por electroforesis en geles de agarosa y secuenciación con el Kit Big Dye Terminator V3.1 Resultados: se identificó la variante patogénica en 15 (88.2%) pacientes no relacionados. La variante p.Gly1609Arg fue identificada en el 52.9% de los pacientes analizados (n=9) sola o en combinación, seguido en frecuencia por p.Ile1425Phe (n=3), y p.Ala1437Thr (n=3) sola o en combinación, un paciente con p.Arg1597Trp y otro con p.Arg1334Trp. Adicionalmente, en el 31.6% (n=6) de los pacientes se identificaron dos variantes patogénicas (dos pacientes con p.Gly1609Arg/p.Ala1437Thr; un paciente p.Gly1609Arg/p.Ser1506Leu; un paciente p.Gly1609Arg/p.Arg1597Trp; un paciente p.Gly1609Arg/p.Val1279Phe; y un paciente p.Ile1628Thr/p.Ser1325Phe). No se identificó variante en dos pacientes (11.8%). Se pudo reclasificar el subtipo EvW tipo 2 en el 40% (n=8) de pacientes. Conclusiones: este es el primer estudio realizado en Colombia que permite identificar la causa genética de EvW, mediante la secuenciación de exones específicos en una cohorte de seguimiento.


Visitas del artículo 186 | Visitas PDF 227


Descargas

Los datos de descarga todavía no están disponibles.
  1. Hernández-Zamora E, Zavala-Hernández C, Quintana-González S, Reyes-Maldonado E. Enfermedad de von Willebrand, biología molecular y diagnóstico. Cir Cir [Internet]. 2015;83(3):255–64. Disponible en: https://doi.org/10.1016/j.circir.2015.05.010 DOI: https://doi.org/10.1016/j.circir.2015.05.010
  2. Woods AI, Blanco AN, Kempfer AC, Paiva J, Bermejo EI, Sánchez Luceros A, et al. Factor von Willebrand y Enfermedad de von Willebrand: nuevos enfoques diagnósticos. Acta Bioquímica Clínica Latinoam [Internet]. 2016;50(2):273–89. Disponible en: https://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-29572016000200012&lng=es.
  3. James PD, Goodeve AC. von Willebrand disease. Genet Med [Internet]. 2011 [cited 2025 Jan 1];13(5):365–76. Disponible en: https://doi.org/10.1097/GIM.0b013e3182035931 DOI: https://doi.org/10.1097/GIM.0b013e3182035931
  4. Ruggeri ZM, Zimmerman TS. von Willebrand Factor and von Willebrand Disease. Blood [Internet]. 1987 [cited 2025 Jan 1];70(4):895–904. Disponible en: https://doi.org/10.1182/blood.V70.4.895.895 DOI: https://doi.org/10.1182/blood.V70.4.895.895
  5. World Federation of Hemophilia. World Federation of Hemophilia Report on the Annual Global Survey 2023 [Internet]. 2023. Disponible en: https://www1.wfh.org/publications/files/pdf-2525.pdf
  6. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost [Internet]. 2006;4(10):2103–14. Disponible en: https://doi.org/10.1111/j.1538-7836.2006.02146.x DOI: https://doi.org/10.1111/j.1538-7836.2006.02146.x
  7. Fressinaud E, Mazurier C, Meyer D. Molecular genetics of type 2 von Willebrand disease. Int J Hematol [Internet]. 2002;75(1):9–18. Disponible en: https://doi.org/10.1007/bf02981973 DOI: https://doi.org/10.1007/BF02981973
  8. Connell NT, Flood VH, Brignardello-Petersen R, Abdul-Kadir R, Arapshian A, Couper S, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv [Internet]. 2021;5(1):301–25. Disponible en: https://doi.org/10.1182/bloodadvances.2020003264 DOI: https://doi.org/10.1182/bloodadvances.2020003264
  9. Itzhar-Baikian N, Boisseau P, Joly B, Veyradier A. Updated overview on von Willebrand disease: focus on the interest of genotyping. Expert Rev Hematol. 2019;12(12):1023–36. Disponible en: https://doi.org/10.1080/17474086.2019.1670638 DOI: https://doi.org/10.1080/17474086.2019.1670638
  10. Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev [Internet]. 2010;24(3):123–34. Disponible en: https://doi.org/10.1016/j.blre.2010.03.003 DOI: https://doi.org/10.1016/j.blre.2010.03.003
  11. Goodeve A. Diagnosing von Willebrand disease: genetic analysis. Hematology [Internet]. 2016;2016(1):678–82. Disponible en: https://doi.org/10.1182/asheducation-2016.1.678 DOI: https://doi.org/10.1182/asheducation-2016.1.678
  12. Stufano F, Baronciani L, Peyvandi F. Diagnosis of von Willebrand Disease: Phenotypic Characterization. WFH eLearning Platf [Internet]. 2017; Disponible en: https://elearning.wfh.org/resource/diagnosis-von-willebrand-disease-phenotypic-characterization/
  13. Favaloro EJ. Diagnosing von Willebrand disease: a short history of laboratory milestones and innovations, plus current status, challenges, and solutions. Semin Thromb Hemost. 2014;40(5):551–70. Disponible en: https://doi.org/10.1055/s-0034-1383546 DOI: https://doi.org/10.1055/s-0034-1383546
  14. Sharma R, Haberichter SL. New advances in the diagnosis of von Willebrand disease. Hematol Am Soc Hematol Educ Progr. 2019;(1):596–600. Disponible en: https://doi.org/10.1182/hematology.2019000064 DOI: https://doi.org/10.1182/hematology.2019000064
  15. James P, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv [Internet]. 2021;5(1):280–300. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33570651https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805340/ DOI: https://doi.org/10.1182/bloodadvances.2020003265
  16. Freitas SDS, Rezende SM, de Oliveira LC, Prezotti ANL, Renni MS, Corsini CA, et al. Genetic variants of VWF gene in type 2 von Willebrand disease. Haemophilia. 2019;25(2):e78–85. Disponible en: https://doi.org/10.1111/hae.13714 DOI: https://doi.org/10.1111/hae.13714
  17. den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. Hum Mutat. 2016 Jun;37(6):564–9. Disponible en: https://doi.org/10.1002/humu.22981 DOI: https://doi.org/10.1002/humu.22981
  18. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med Off J Am Coll Med Genet. 2015 May;17(5):405–24. Disponible en: https://doi.org/10.1038/gim.2015.30 DOI: https://doi.org/10.1038/gim.2015.30
  19. Borràs N, Batlle J, Pérez-Rodríguez A, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, et al. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients. Haematologica. 2017 Dec;102(12):2005–14. Disponible en: https://doi.org/10.3324/haematol.2017.168765 DOI: https://doi.org/10.3324/haematol.2017.168765
  20. Liang Q, Qin H, Ding Q, Xie X, Wu R, Wang H, et al. Molecular and clinical profile of VWD in a large cohort of Chinese population: application of next generation sequencing and CNVplex(®) technique. Thromb Haemost. 2017;117(8):1534–48. Disponible en: https://doi.org/10.1160/th16-10-0794 DOI: https://doi.org/10.1160/TH16-10-0794
  21. Seidizadeh O, Baronciani L, Pagliari MT, Cozzi G, Colpani P, Cairo A, et al. Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2. Blood Adv. 2022 Jul;6(13):4031–40. Disponible en: https://doi.org/10.1182/bloodadvances.2022007216 DOI: https://doi.org/10.1182/bloodadvances.2022007216
  22. Vangenechten I, Smejkal P, Zapletal O, Michiels JJ, Berneman Z, Zavrelova J, et al. Analysis of von Willebrand Disease in the South Moravian Population (Czech Republic): Results from the BRNO-VWD Study. Thromb Haemost. 2019 Apr;119(4):594–605. Disponible en: https://doi.org/10.1055/s-0039-1678528 DOI: https://doi.org/10.1055/s-0039-1678528
  23. Woods AI, Kempfer AC, Paiva J, Blanco AN, Sánchez-Luceros A, Lazzari MA. Diagnosis of von Willebrand disease in Argentina: a single institution experience. Ann Blood; Vol 2, No 9 (December 2017) Ann blood [Internet]. 2017; Disponible en: https://aob.amegroups.org/article/view/4207
  24. Maas DPMSM, Atiq F, Blijlevens NMA, Brons PPT, Krouwel S, Laros-van Gorkom BAP, et al. Von Willebrand disease type 2M: Correlation between genotype and phenotype. J Thromb Haemost. 2022 Feb;20(2):316–27. Disponible en: https://doi.org/10.1111/jth.15586 DOI: https://doi.org/10.1111/jth.15586
  25. Choi SJ, Lee EY, Kim HJ, Lee KA, Song J, Choi JR, et al. A Gly1609Arg missense mutation in the vWF gene in a Korean patient with von Willebrand disease type 2A. Ann Clin Lab Sci. 2012;42(1):98–102. Disponible en: http://www.annclinlabsci.org/content/42/1/98.long
  26. Hassenpflug WA, Budde U, Obser T, Angerhaus D, Drewke E, Schneppenheim S, et al. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood [Internet]. 2006;107(6):2339–45. Disponible en: https://www.sciencedirect.com/science/article/pii/S0006497120656798 DOI: https://doi.org/10.1182/blood-2005-04-1758
  27. Jacobi PM, Gill JC, Flood VH, Jakab DA, Friedman KD, Haberichter SL. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. Blood. 2012 May;119(19):4543–53. Disponible en: https://doi.org/10.1182/blood-2011-06-360875 DOI: https://doi.org/10.1182/blood-2011-06-360875
  28. Yunis LK, Linares A, Cabrera E, Yunis JJ. Systematic molecular analysis of hemophilia A patients from Colombia. Genet Mol Biol. 2018;41(4):750–7. Disponible en: https://doi.org/10.1590/1678-4685-gmb-2017-0072 DOI: https://doi.org/10.1590/1678-4685-gmb-2017-0072
  29. Casaña P, Martínez F, Haya S, Tavares A, Aznar JA. New mutations in exon 28 of the von Willebrand factor gene detected in patients with different types of von Willebrand’s disease. Haematologica. 2001 Apr;86(4):414–9. Disponible en: https://haematologica.org/haematologica/article/view/1997
  30. Gadisseur A, van der Planken M, Schroyens W, Berneman Z, Michiels JJ. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene. Acta Haematol. 2009;121(2–3):145–53. Disponible en: https://doi.org/10.1159/000214855 DOI: https://doi.org/10.1159/000214855
  31. Gastaldi G, Rasore-Quartino A, Galletti A, Campanella A, Barone E, Mannucci PM. Coexistence of haemophilia A and von Willebrand’s disease in the same kindred. Scand J Haematol. 1978 May;20(5):423–8. Disponible en: https://doi.org/10.1111/j.1600-0609.1978.tb02478.x DOI: https://doi.org/10.1111/j.1600-0609.1978.tb02478.x
  32. Kavakli K, BALKAN C, AKIN M, KARAPINAR DY, AY Y. Co-existing mild haemophilia A with mild type 1 von willebrand disease: Case report. Uluslararası Hematol Derg [Internet]. 2011;21(2):111–4. Disponible en: https://doi.org/10.4999/uhod.10048 DOI: https://doi.org/10.4999/uhod.10048
  33. O’Brien SH, Ritchey AK, Ragni M V. Combined clotting factor deficiencies: experience at a single hemophilia treatment center. Haemophilia. 2007 Jan;13(1):26–9. Disponible en: https://doi.org/10.1111/j.1365-2516.2006.01389.x DOI: https://doi.org/10.1111/j.1365-2516.2006.01389.x
  34. Favaloro EJ, Pasalic L, Curnow J. Type 2M and Type 2A von Willebrand Disease: Similar but Different. Semin Thromb Hemost. 2016;42(5):483–97. Disponible en: https://doi.org/10.1055/s-0036-1579641 DOI: https://doi.org/10.1055/s-0036-1579641
  35. Favaloro EJ, Bonar RA, Mohammed S, Arbelaez A, Niemann J, Freney R, et al. Type 2M von Willebrand disease - more often misidentified than correctly identified. Haemophilia. 2016 May;22(3):e145-55. Disponible en: https://doi.org/10.1111/hae.12903 DOI: https://doi.org/10.1111/hae.12903
  36. Berber E, Pehlevan F, Akin M, Capan OY, Kavakli K, Çaglayan SH. A common VWF exon 28 haplotype in the Turkish population. Clin Appl Thromb Off J Int Acad Clin Appl Thromb. 2013 Sep;19(5):550–6. Disponible en: https://doi.org/10.1177/1076029612441054 DOI: https://doi.org/10.1177/1076029612441054
  37. Culpan D, Standen G, Wood N, Mazurier C, Gaucher C, Bidwell J. Rapid mutation screening in type 2A von Willebrand’s disease using universal heteroduplex generators. Br J Haematol. 1997 Mar;96(3):464–9. Disponible en: https://doi.org/10.1046/j.1365-2141.1997.d01-2054.x DOI: https://doi.org/10.1046/j.1365-2141.1997.d01-2054.x
  38. Shen MC, Chen M, Ma GC, Chang SP, Lin CY, Lin BD, et al. De novo mutation and somatic mosaicism of gene mutation in type 2A, 2B and 2M VWD. Thromb J. 2016;14(Suppl 1):36. Disponible en: https://doi.org/10.1186/s12959-016-0092-2 DOI: https://doi.org/10.1186/s12959-016-0092-2
  39. Baronciani L, Federici AB, Cozzi G, Canciani MT, Mannucci PMM. von Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M. Vol. 4, Journal of thrombosis and haemostasis : JTH. England; 2006. p. 2088–90. Disponible en: https://doi.org/10.1111/j.1538-7836.2006.02069.x DOI: https://doi.org/10.1111/j.1538-7836.2006.02069.x
  40. Pruss CM, Golder M, Bryant A, Hegadorn C, Haberichter S, Lillicrap D. Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W. J Thromb Haemost. 2012 May;10(5):940–50. Disponible en: https://doi.org/10.1111/j.1538-7836.2012.04675.x DOI: https://doi.org/10.1111/j.1538-7836.2012.04675.x
  41. Starke RD, Paschalaki KE, Dyer CEF, Harrison-Lavoie KJ, Cutler JA, McKinnon TAJ, et al. Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells. Blood. 2013 Apr;121(14):2773–84. Disponible en: https://doi.org/10.1182/blood-2012-06-435727 DOI: https://doi.org/10.1182/blood-2012-06-435727
  42. Xu AJ, Springer TA. Mechanisms by which von Willebrand disease mutations destabilize the A2 domain. J Biol Chem. 2013 Mar;288(9):6317–24. Disponible en: https://doi.org/10.1074/jbc.m112.422618 DOI: https://doi.org/10.1074/jbc.M112.422618
  43. Eikenboom JC, Castaman G, Vos HL, Bertina RM, Rodeghiero F. Characterization of the genetic defects in recessive type 1 and type 3 von Willebrand disease patients of Italian origin. Thromb Haemost. 1998 Apr;79(4):709–17. Disponible en: https://doi.org/10.1055/s-0037-1615050 DOI: https://doi.org/10.1055/s-0037-1615050
  44. Elayaperumal S, Fouzia NA, Biswas A, Nair SC, Viswabandya A, George B, et al. Type-3 von Willebrand disease in India-Clinical spectrum and molecular profile. Haemophilia. 2018 Nov;24(6):930–40. Disponible en: https://doi.org/10.1111/hae.13542 DOI: https://doi.org/10.1111/hae.13542
  45. Veyradier A, Boisseau P, Fressinaud E, Caron C, Ternisien C, Giraud M, et al. A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture. Medicine (Baltimore). 2016 Mar;95(11):e3038. Disponible en: https://doi.org/10.1097/md.0000000000003038 DOI: https://doi.org/10.1097/MD.0000000000003038
  46. Meyer D, Fressinaud E, Gaucher C, Lavergne JM, Hilbert L, Ribba AS, et al. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease. Thromb Haemost. 1997 Jul;78(1):451–6. Disponible en: https://doi.org/10.1055/s-0038-1657568 DOI: https://doi.org/10.1055/s-0038-1657568
  47. Tischer A, Madde P, Moon-Tasson L, Auton M. Misfolding of vWF to pathologically disordered conformations impacts the severity of von Willebrand disease. Biophys J. 2014 Sep;107(5):1185–95. Disponible en: https://doi.org/10.1016/j.bpj.2014.07.026 DOI: https://doi.org/10.1016/j.bpj.2014.07.026
  48. Vangenechten I, Smejkal P, Zavrelova J, Zapletal O, Wild A, Michiels JJ, et al. Analysis of von Willebrand Disease in the “Heart of Europe”. TH open companion J to Thromb Haemost. 2022 Oct;6(4):e335–46. Disponible en: https://doi.org/10.1055/s-0042-1757635 DOI: https://doi.org/10.1055/s-0042-1757635
  49. Fidalgo T, Salvado R, Corrales I, Pinto SC, Borràs N, Oliveira A, et al. Genotype-phenotype correlation in a cohort of Portuguese patients comprising the entire spectrum of VWD types: impact of NGS. Thromb Haemost. 2016 Jul;116(1):17–31. Disponible en: https://doi.org/10.1160/th15-07-0604 DOI: https://doi.org/10.1160/TH15-07-0604
  50. Arbelaez A, Niemann J, Freney R, Othman M, Emsley J, Mohammed S, et al. “Bleeding in the jungle”. Am J Hematol. 2015 Sep;90(9):843–6. Disponible en: https://doi.org/10.1002/ajh.24032 DOI: https://doi.org/10.1002/ajh.24032
  51. Baronciani L, Goodeve A, Peyvandi F. Molecular diagnosis of von Willebrand disease. Haemophilia [Internet]. 2017;23(2):188–97. Disponible en: https://doi.org/10.1111/hae.13175 DOI: https://doi.org/10.1111/hae.13175
  52. Seidizadeh O, Peyvandi F, Mannucci PM. Von Willebrand disease type 2N: An update. J Thromb Haemost. 2021 Apr;19(4):909–16. Disponible en: https://doi.org/10.1111/jth.15247 DOI: https://doi.org/10.1111/jth.15247
Sistema OJS 3.4.0.7 - Metabiblioteca |